Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer

Langley, Ruth E., Godsland, Ian F., Kynaston, Howard ORCID: https://orcid.org/0000-0003-1902-9930, Clarke, Noel W., Rosen, Stuart D., Morgan, Rachel C., Pollock, Philip, Kockelbergh, Roger, Lalani, El-Nasir, Dearnaley, David, Parmar, Mahesh and Abel, Paul D. 2008. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU International 102 (4) , pp. 442-445. 10.1111/j.1464-410X.2008.07583.x

Full text not available from this repository.

Abstract

OBJECTIVE: To assess the hormonal effects of Fem7® (Merck, KGaA, Darmstadt, Germany) 100 µg transdermal oestrogen patches on men undergoing first-line androgen-deprivation therapy for prostate cancer. PATIENTS AND METHODS: PATCH is a multicentre, randomized, phase II trial for men with locally advanced or metastatic prostate cancer, comparing luteinizing hormone-releasing hormone agonist therapy with oestrogen patches. To assess the dosing schedule for the patches, as this was the first time that this brand of patch had been used in men, and to reassure patients and participating clinicians, the Independent Data Monitoring Committee agreed to early release of hormonal data from this study. RESULTS: Oestradiol, testosterone and prostate-specific antigen (PSA) levels are presented for the first group of 14 patients who received the patches (with 1 withdrawal) and for whom there were ≥12 weeks of follow-up by March 2007. After 12 weeks, testosterone levels (nmol/L) in eight of the 13 patients were <1.7, two were 1.7–2 and three were >2. The median (range) serum oestradiol levels was 442 (52.1–1542) pmol/L and all patients had a PSA response, with eight having a PSA level of <4 ng/mL. CONCLUSION: These results confirm that oestrogen patches produce castrate levels of testosterone and concomitant PSA responses. They also highlighted the potential differences between different brands of oestrogen patches, and the need to monitor hormonal response, toxicity and efficacy until more experience with oestrogen patches for this clinical indication is obtained. The number of patches recommended in the PATCH study has now been increased.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	transdermal oestrogen patches; hormone therapy; prostate cancer; randomized controlled trial
Publisher:	Wiley-Blackwell
ISSN:	1464-4096
Last Modified:	24 Oct 2022 11:33
URI:	https://orca.cardiff.ac.uk/id/eprint/48542

Citation Data

Cited 36 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item